Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia

• Published in: International journal of hematology Vol. 98; no. 4; pp. 483 - 486
• Main Authors: Sgherza, Nicola, Russo Rossi, Antonella Vita, Colonna, Paolo, Carluccio, Paola, Delia, Mario, Specchia, Giorgina
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.10.2013; Springer; Springer Nature B.V
• Subjects: Aged; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Brugada Syndrome - complications; Brugada Syndrome - diagnosis; Brugada Syndrome - therapy; Cardiac dysrhythmias; Cardiology. Vascular system; Case Report; Electrocardiography; Heart; Hematologic and hematopoietic diseases; Hematology; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Medicine; Medicine & Public Health; Oncology; Protein Kinase Inhibitors - therapeutic use; Treatment Outcome; Brugada syndrome; Tyrosine kinase inhibitors; Chronic myeloid leukemia; Human; Arrhythmia; Hematology; Tyrosine kinase inhibitor; Chronic myelogenous leukemia; Cardiovascular disease; Malignant hemopathy; Myeloproliferative syndrome; Heart disease; Cancer
• ISSN: 0925-5710; 1865-3774; 1865-3774
• DOI: 10.1007/s12185-013-1395-8

The treatment and prognosis of chronic myeloid leukemia have dramatically changed since the introduction of tyrosine kinase inhibitors, but although several clinical trials have examined their safety with respect to heart function, no data are yet available about the use of these drugs in patients with Brugada syndrome. We report a case of Brugada syndrome diagnosed during tyrosine kinase inhibitor therapy in a 69-year-old Caucasian male with meningioma and chronic myeloid leukemia. This case report highlights the importance of an integrated approach among hematologists and cardiologists to ensure appropriate treatment with tyrosine kinase inhibitors in patients affected by chronic myeloid leukemia who also suffer from Brugada syndrome.